There is no apparent risk for people who are HBsAg negative and anti-Hbc and anti-HBc positive.
4.If HBsAg is positive, then a hepatitis B viral load test should be done before, during and immediately after hep C treatment.Though at a very low risk of reactivation, people who have resolved HBV infection, need periodical monitoring during their hep C treatment.
5.Those prone to hepatitis B need to get vaccinated.
According to FDA, there were 24 confirmed cases of reactivation in HBV/HCV coinfected patients treated with DAAs between November 2013 and July 2016.Two died, one needed liver transplant and three experienced hepatic decomposition. Half the patients received hep B treatment and most of them showed a decrease in HBV DNA.
The FDA confirmed that HBV reactivation usually occurred within 4 to 8 weeks after starting treatment with DAA and was visible in people with detectable and undetectable HBV DNA at baseline.